These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

431 related articles for article (PubMed ID: 31155643)

  • 1. A validation study of the European Society of Cardiology guidelines for risk stratification of sudden cardiac death in childhood hypertrophic cardiomyopathy.
    Norrish G; Ding T; Field E; McLeod K; Ilina M; Stuart G; Bhole V; Uzun O; Brown E; Daubeney PEF; Lota A; Linter K; Mathur S; Bharucha T; Kok KL; Adwani S; Jones CB; Reinhardt Z; Omar RZ; Kaski JP
    Europace; 2019 Oct; 21(10):1559-1565. PubMed ID: 31155643
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A validation study of the 2003 American College of Cardiology/European Society of Cardiology and 2011 American College of Cardiology Foundation/American Heart Association risk stratification and treatment algorithms for sudden cardiac death in patients with hypertrophic cardiomyopathy.
    O'Mahony C; Tome-Esteban M; Lambiase PD; Pantazis A; Dickie S; McKenna WJ; Elliott PM
    Heart; 2013 Apr; 99(8):534-41. PubMed ID: 23339826
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validation of the 2014 European Society of Cardiology guidelines risk prediction model for the primary prevention of sudden cardiac death in hypertrophic cardiomyopathy.
    Vriesendorp PA; Schinkel AF; Liebregts M; Theuns DA; van Cleemput J; Ten Cate FJ; Willems R; Michels M
    Circ Arrhythm Electrophysiol; 2015 Aug; 8(4):829-35. PubMed ID: 25922410
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predicting therapies in Japanese hypertrophic cardiomyopathy patients with an implantable cardioverter-defibrillator using the 2014 European Society of Cardiology guidelines.
    Nakano M; Kondo Y; Nakano M; Kajiyama T; Miyazawa K; Hayashi T; Ito R; Takahira H; Kobayashi Y
    Heart Vessels; 2021 Jan; 36(1):99-104. PubMed ID: 32666207
    [TBL] [Abstract][Full Text] [Related]  

  • 5. International External Validation Study of the 2014 European Society of Cardiology Guidelines on Sudden Cardiac Death Prevention in Hypertrophic Cardiomyopathy (EVIDENCE-HCM).
    O'Mahony C; Jichi F; Ommen SR; Christiaans I; Arbustini E; Garcia-Pavia P; Cecchi F; Olivotto I; Kitaoka H; Gotsman I; Carr-White G; Mogensen J; Antoniades L; Mohiddin SA; Maurer MS; Tang HC; Geske JB; Siontis KC; Mahmoud KD; Vermeer A; Wilde A; Favalli V; Guttmann OP; Gallego-Delgado M; Dominguez F; Tanini I; Kubo T; Keren A; Bueser T; Waters S; Issa IF; Malcolmson J; Burns T; Sekhri N; Hoeger CW; Omar RZ; Elliott PM
    Circulation; 2018 Mar; 137(10):1015-1023. PubMed ID: 29191938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improvement in sudden cardiac death risk prediction by the enhanced American College of Cardiology/American Heart Association strategy in Chinese patients with hypertrophic cardiomyopathy.
    Liu J; Wu G; Zhang C; Ruan J; Wang D; Zhang M; Wang L; Yang Y; Li X; Wang Y; Hui R; Zou Y; Kang L; Wang J; Song L
    Heart Rhythm; 2020 Oct; 17(10):1658-1663. PubMed ID: 32311532
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a Novel Risk Prediction Model for Sudden Cardiac Death in Childhood Hypertrophic Cardiomyopathy (HCM Risk-Kids).
    Norrish G; Ding T; Field E; Ziólkowska L; Olivotto I; Limongelli G; Anastasakis A; Weintraub R; Biagini E; Ragni L; Prendiville T; Duignan S; McLeod K; Ilina M; Fernández A; Bökenkamp R; Baban A; Kubuš P; Daubeney PEF; Sarquella-Brugada G; Cesar S; Marrone C; Bhole V; Medrano C; Uzun O; Brown E; Gran F; Castro FJ; Stuart G; Vignati G; Barriales-Villa R; Guereta LG; Adwani S; Linter K; Bharucha T; Garcia-Pavia P; Rasmussen TB; Calcagnino MM; Jones CB; De Wilde H; Toru-Kubo J; Felice T; Mogensen J; Mathur S; Reinhardt Z; O'Mahony C; Elliott PM; Omar RZ; Kaski JP
    JAMA Cardiol; 2019 Sep; 4(9):918-927. PubMed ID: 31411652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The amount of late gadolinium enhancement outperforms current guideline-recommended criteria in the identification of patients with hypertrophic cardiomyopathy at risk of sudden cardiac death.
    Freitas P; Ferreira AM; Arteaga-Fernández E; de Oliveira Antunes M; Mesquita J; Abecasis J; Marques H; Saraiva C; Matos DN; Rodrigues R; Cardim N; Mady C; Rochitte CE
    J Cardiovasc Magn Reson; 2019 Aug; 21(1):50. PubMed ID: 31412875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Validation of the 2014 European Society of Cardiology Sudden Cardiac Death Risk Prediction Model Among Various Phenotypes in Japanese Patients With Hypertrophic Cardiomyopathy.
    Nakagawa S; Okada A; Nishimura K; Hamatani Y; Amano M; Takahama H; Amaki M; Hasegawa T; Kanzaki H; Kusano K; Yasuda S; Izumi C
    Am J Cardiol; 2018 Dec; 122(11):1939-1946. PubMed ID: 30293654
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk factors for sudden cardiac death in childhood hypertrophic cardiomyopathy: A systematic review and meta-analysis.
    Norrish G; Cantarutti N; Pissaridou E; Ridout DA; Limongelli G; Elliott PM; Kaski JP
    Eur J Prev Cardiol; 2017 Jul; 24(11):1220-1230. PubMed ID: 28482693
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Validation of the new American College of Cardiology/American Heart Association Guidelines for the risk stratification of sudden cardiac death in a large Mediterranean cohort with Hypertrophic Cardiomyopathy.
    Zegkos T; Tziomalos G; Parcharidou D; Ntelios D; Papanastasiou CA; Karagiannidis E; Gossios T; Rouskas P; Katranas S; Paraskevaidis S; Karvounis H; Efthimiadis G
    Hellenic J Cardiol; 2022; 63():15-21. PubMed ID: 34147674
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management and outcomes of hypertrophic cardiomyopathy in young adults.
    Baron É; Karam N; Donal E; Puscas T; Mirabel M; Bacher A; Wahbi K; Mazzella JM; Jeunemaitre X; Reant P; Hagège A;
    Arch Cardiovasc Dis; 2021; 114(6-7):465-473. PubMed ID: 33744178
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Appropriate and inappropriate shocks in hypertrophic cardiomyopathy patients with subcutaneous implantable cardioverter-defibrillators: An international multicenter study.
    Nazer B; Dale Z; Carrassa G; Reza N; Ustunkaya T; Papoutsidakis N; Gray A; Howell SJ; Elman MR; Pieragnoli P; Ricciardi G; Jacoby D; Frankel DS; Owens A; Olivotto I; Heitner SB
    Heart Rhythm; 2020 Jul; 17(7):1107-1114. PubMed ID: 32084597
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Independent Assessment of the European Society of Cardiology Sudden Death Risk Model for Hypertrophic Cardiomyopathy.
    Maron BJ; Casey SA; Chan RH; Garberich RF; Rowin EJ; Maron MS
    Am J Cardiol; 2015 Sep; 116(5):757-64. PubMed ID: 26183790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic Role of Late Gadolinium Enhancement in Patients With Hypertrophic Cardiomyopathy and Low-to-Intermediate Sudden Cardiac Death Risk Score.
    Todiere G; Nugara C; Gentile G; Negri F; Bianco F; Falletta C; Novo G; Di Bella G; De Caterina R; Zachara E; Re F; Clemenza F; Sinagra G; Emdin M; Aquaro GD
    Am J Cardiol; 2019 Oct; 124(8):1286-1292. PubMed ID: 31447011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Validated Model for Sudden Cardiac Death Risk Prediction in Pediatric Hypertrophic Cardiomyopathy.
    Miron A; Lafreniere-Roula M; Steve Fan CP; Armstrong KR; Dragulescu A; Papaz T; Manlhiot C; Kaufman B; Butts RJ; Gardin L; Stephenson EA; Howard TS; Aziz PF; Balaji S; Ladouceur VB; Benson LN; Colan SD; Godown J; Henderson HT; Ingles J; Jeewa A; Jefferies JL; Lal AK; Mathew J; Jean-St-Michel E; Michels M; Nakano SJ; Olivotto I; Parent JJ; Pereira AC; Semsarian C; Whitehill RD; Wittekind SG; Russell MW; Conway J; Richmond ME; Villa C; Weintraub RG; Rossano JW; Kantor PF; Ho CY; Mital S
    Circulation; 2020 Jul; 142(3):217-229. PubMed ID: 32418493
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Validation of the HCM Risk-SCD model in patients with hypertrophic cardiomyopathy following alcohol septal ablation.
    Liebregts M; Faber L; Jensen MK; Vriesendorp PA; Hansen PR; Seggewiss H; Horstkotte D; Adlova R; Michels M; Bundgaard H; Ten Berg JM; Veselka J
    Europace; 2018 Sep; 20(FI2):f198-f203. PubMed ID: 29016960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Programmed ventricular stimulation predicts arrhythmic events and survival in hypertrophic cardiomyopathy.
    Gatzoulis KA; Georgopoulos S; Antoniou CK; Anastasakis A; Dilaveris P; Arsenos P; Sideris S; Tsiachris D; Archontakis S; Sotiropoulos E; Theopistou A; Skiadas I; Kallikazaros I; Stefanadis C; Tousoulis D
    Int J Cardiol; 2018 Mar; 254():175-181. PubMed ID: 29407088
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Risk stratification of sudden death in hypertrophic cardiomyopathy in 2016].
    Dubourg O; Charron P; Sirol M; Siam-Tsieu V; Mansencal N
    Presse Med; 2016 Oct; 45(10):903-910. PubMed ID: 27234906
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Importance of newer cardiac magnetic resonance-based risk markers for sudden death prevention in hypertrophic cardiomyopathy: An international multicenter study.
    Rowin EJ; Maron MS; Adler A; Albano AJ; Varnava AM; Spears D; Marsy D; Heitner SB; Cohen E; Leong KMW; Winters SL; Martinez MW; Koethe BC; Rakowski H; Maron BJ
    Heart Rhythm; 2022 May; 19(5):782-789. PubMed ID: 34933112
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.